The DOI matches its Crossref record.
VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The populations in the trials of the two triplet regimens differed from the CARTITUDE-4 trial population, and lenalidomide resistance was not a criterion for inclusion in those trials.
“However, the populations in these trials differed from our trial population, and lenalidomide resistance was not a criterion for inclusion.”
From Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) · cites this paper as [27]
The Background identifies IKEMA as a trial in relapsed multiple myeloma, but neither it nor the Methods specifies whether lenalidomide resistance was an inclusion criterion. Our copy also does not compare IKEMA’s population with CARTITUDE-4’s. Searches for lenalidomide resistance and eligibility criteria found no passage resolving either point. (LLM, conf=0.74)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Self-citation
Metadata
- Authors
- Moreau, P., Dimopoulos, M. A. C., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Casca, F., Mace, S., Singh, E., Risse, M.-L., & Martin, T.
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- National and Kapodistrian University of Athens (GR)
- Translational Genomics Research Institute (US)
- University College Hospital (GB)
- Hospital Mãe de Deus (BR)
- Centre Hospitalier Universitaire de Lille (FR)
- Sanofi (France) (FR)
- University of California, San Francisco (US)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 33
- Issue
- 6
- Pages
- 664-665
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4280488597
- Cited by
- 18
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 12 · 2022: 4
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- isatuximab, carfilzomib, dexamethasone, relapsed multiple myeloma, anti-CD38 monoclonal antibody, progression-free survival, depth of response, combination therapy, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
